PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
74.78%
EBIT growth of 74.78% while Healthcare median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
74.78%
Operating income growth of 74.78% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand.
64.85%
Net income growth of 64.85% while Healthcare median is zero. Walter Schloss might see potential if moderate gains can keep rising.
64.71%
EPS growth of 64.71% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
64.71%
Diluted EPS growth of 64.71% while Healthcare median is zero. Walter Schloss might see a slight edge that could improve over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-60.52%
Negative OCF growth while Healthcare median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-60.52%
Negative FCF growth while Healthcare median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
51.61%
OCF/share CAGR of 51.61% while Healthcare median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
51.61%
OCF/share CAGR of 51.61% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
51.61%
3Y OCF/share growth of 51.61% while Healthcare median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
66.06%
Net income/share CAGR of 66.06% while Healthcare median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
66.06%
Net income/share CAGR of 66.06% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
66.06%
3Y net income/share CAGR of 66.06% while Healthcare median is zero. Walter Schloss might see a small advantage that can be scaled further.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.06%
Assets shrink while Healthcare median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-5.28%
Negative BV/share change while Healthcare median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
11.50%
Debt growth of 11.50% while Healthcare median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
-73.61%
SG&A decline while Healthcare grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.